A Gan Ding

Quick links to important sections

A Gan Ding

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of A Gan Ding

What is A Gan Ding?

A Gan Ding is a brand name for the pharmaceutical medication adefovir dipivoxil. It is an antiviral drug belonging to a class known as nucleotide analogs. This medication is specifically designed to manage chronic infections caused by the hepatitis B virus (HBV).

Mechanism of Action

The primary function of A Gan Ding is to interfere with the way the hepatitis B virus replicates within the body. It works by inhibiting HBV DNA polymerase, an enzyme that the virus requires to copy its genetic material. By blocking this process, the medication helps to reduce the total amount of the virus (viral load) in the bloodstream.

Clinical Purpose

A Gan Ding is used in the long-term management of chronic hepatitis B in adults who show evidence of active viral replication. This is often indicated by persistent elevations in liver enzymes (such as ALT or AST) or histological evidence of active liver disease. The goals of using this medication include:

  • Decreasing the amount of HBV in the body.
  • Reducing the risk of liver damage and inflammation.
  • Improving liver function over time.

Nature of Treatment

It is important to understand that A Gan Ding is a treatment, not a cure, for hepatitis B. While it effectively suppresses the virus and can prevent the progression of liver disease, it does not eliminate the virus from the body entirely. Patients typically require long-term monitoring by a healthcare professional to assess the effectiveness of the treatment and the health of the liver.

Regulatory References

  1. Adefovir (LiverTox)

What side effects are possible with A Gan Ding?

Possible side effects and safety information

A Gan Ding, containing Adefovir Dipivoxil, has a safety profile documented by official regulatory bodies, classifying adverse reactions by frequency and physiological system affected.

Reactions classified as common in official labeling are primarily related to the nervous and gastrointestinal systems. These include headache, diarrhea, abdominal pain, nausea, flatulence, and general asthenia (weakness). The regulatory data also documents a common rise in serum creatinine levels, reflecting an effect on clinical chemistry.


Serious Adverse Reactions and Systemic Concerns

The regulatory safety profile highlights several serious, systemic concerns. These include the potential for Lactic Acidosis and Severe Hepatomegaly with Steatosis, which are classified as rare but potentially fatal. A major safety pattern is the risk of Severe Acute Exacerbation of Hepatitis B observed in some patients after treatment cessation, which involves the hepato-biliary system.

Nephrotoxicity or Renal Impairment is an uncommon but serious adverse reaction. The risk of this effect is noted to increase with the long-term administration of the medicine. Individuals with pre-existing renal impairment are documented to be at a higher risk of developing this toxicity.


Safety Restrictions and Monitoring

Official labels address specific safety constraints, noting that co-administration with other drugs affecting renal tubular secretion may elevate toxicity risk. Furthermore, in patients co-infected with HIV-1 who are not receiving active Antiretroviral Therapy (ART), the use of this medicine may potentially select for HIV-1 resistance.

This structured safety information establishes the distinction between common, non-serious effects and rare but clinically critical risks, defining the official safety constraints related to the hepatic and renal systems.

Overdose and Emergency Response

Overdose and When to Seek Help

If an overdose of A Gan Ding (Adefovir Dipivoxil) is suspected, regulatory information explicitly requires seeking immediate medical attention by contacting a poison control center or emergency services. This urgent action is necessary because the drug's official overdose profile involves serious, organ-specific risks.

Documented Manifestations and Severe Risks

The dose-limiting toxicity documented in high-exposure scenarios is nephrotoxicity, or severe kidney injury, which may lead to renal failure. Signs include laboratory changes such as increased serum creatinine and low serum phosphate levels (hypophosphatemia).

Furthermore, the regulatory label highlights the risk of Lactic Acidosis and Severe Hepatomegaly with Steatosis, which are severe, potentially life-threatening complications associated with the class of antiviral agents to which Adefovir Dipivoxil belongs. Patients with pre-existing renal impairment are noted to be at an increased risk of toxicity during overexposure.

Overdose Management and Antidote Status

Regulatory guidance states that there is no specific antidote known for an A Gan Ding overdose. Management focuses on supportive treatment and clinical monitoring for signs of systemic and organ toxicity, especially renal function. Adefovir is known to be partially removed from the body by the documented supportive procedure of hemodialysis.

Therapeutic Uses of A Gan Ding

The therapeutic utility of this medicinal entity, known traditionally as Lingzhi or Reishi, is relevant across several key symptomatic domains. It is commonly used to help with symptoms related to systemic imbalance and those that interfere with daily functioning. It is often applied across domains where additional symptomatic support is needed, addressing symptom clusters that may become intense or disruptive.

Common areas of application include the symptomatic domains of stress, sleep difficulty, and low vitality during periods of heightened systemic burden.

Quick Fact: Relevance for Symptom Management

This product is generally considered relevant in contexts involving temporary physiological imbalance. It may assist with maintaining a sense of stability when symptoms are more noticeable and contributes to easing day-to-day comfort. It is used in conditions where symptoms of general weakness and depletion create noticeable physiological strain, generally supporting overall well-being and helping patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH NCBI Bookshelf overview of Lingzhi/Reishi

Eligibility and Restrictions for Use

The eligibility for using A Gan Ding, which contains Adefovir Dipivoxil, is strictly defined by regulatory authorities based on a patient's age, kidney function, and co-existing medical conditions.

Category Official Regulatory Statement
Populations Allowed Adults and adolescents 12 years of age and older with chronic Hepatitis B (HBV) and compensated liver function [FDA Label].
Contraindicated Populations Patients with known hypersensitivity to the active ingredient or any component. Concurrent use with products containing tenofovir disoproxil fumarate or tenofovir alafenamide [FDA Label].
Age-Related Rules Not recommended for children less than 12 years of age [FDA Label]. Caution is advised for older adult patients (ge 65 years) due to potential age-related decline in renal function [EMA SmPC].
Condition-Specific Rules Renal Impairment: Use requires official dose interval adjustment for patients with creatinine clearance < 50 mL/min. Use is not recommended in adolescents with underlying renal dysfunction due to lack of study data [FDA Label].
Special Caution HIV Co-infection: Patients with HBV and untreated or unrecognized HIV infection should not use this medicine due to the risk of developing HIV resistance [NIH LiverTox].
Pregnancy and Lactation Pregnancy: Data from the pregnancy registry are insufficient to adequately assess risk [FDA Label]. Lactation: It is unknown if Adefovir is present in human milk; breastfeeding is not recommended [NIH MedlinePlus].

The official eligibility profile outlines formal restrictions and requirements for dose management in restricted populations, such as those with reduced kidney function. These rules determine who is eligible for use and who is formally excluded from treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific co-administration restrictions and considerations for A Gan Ding (Adefovir Dipivoxil), primarily focusing on interactions related to kidney function and viral therapy.

Documented Interaction Classifications

Classification Interacting Agents and Requirement
Formal Restriction Co-administration with Tenofovir-containing products is formally classified as a contraindicated combination or not recommended by regulatory bodies.
Nephrotoxicity Risk Concomitant use with known nephrotoxic agents (e.g., Amphotericin B, Cyclosporine, certain NSAIDs) results in an increased risk of additive nephrotoxicity.
Transporter Competition Agents eliminated via active renal tubular secretion may compete with Adefovir, potentially increasing serum concentration of Adefovir or the co-administered drug (e.g., Cidofovir is noted).

Other Official Interaction Notes

Adefovir Dipivoxil has a low potential for CYP450-mediated interactions, as the active drug is officially stated to neither inhibit nor serve as a substrate for major human CYP enzymes. The absorption of the medicine is not significantly affected by food and may be taken without regard to meals. It is also noted that the interaction risks related to renal function are heightened in patients with pre-existing kidney dysfunction, a population-specific consideration present in regulatory labeling.

Mechanism of Action

Adefovir's action is defined by the selective interference of its active metabolite, Adefovir Diphosphate ( ADV-DP), with the viral replication process inside infected liver cells.

Competitive Inhibition of Viral DNA Polymerase

The active metabolite targets the Hepatitis B Virus (HBV) DNA Polymerase through molecular mimicry, acting as a competitive inhibitor against the natural building block ( dATP). This interaction inhibits the polymerase's ability to synthesize new genetic material, a molecular step necessary for viral proliferation.

Obligate Termination of the Replication Cascade

Once incorporated into the growing viral DNA strand, ADV-DP causes obligate chain termination because it structurally lacks the necessary chemical group to link the next nucleotide. This molecular arrest limits the formation of new, complete viral genomes, which results in reduced production and release of new infectious particles. The mechanism results in a decrease in the concentration of serum HBV DNA.

Dosage and Administration Information

Administration and Dosing Regimen

A Gan Ding (Adefovir Dipivoxil) is administered exclusively for oral use as a film-coated tablet. The standard dosage regimen for adults is a single 10 mg tablet taken once daily. This 10 mg represents the maximum prescribed dose and must not be exceeded.

The medicine offers flexibility in administration timing; it may be taken with or without food, as its absorption is independent of meal consumption.

Use Patterns and Population-Specific Rules

Treatment with this medicine is typically a long-term process for the management of the chronic underlying condition, as the optimal duration of therapy remains undetermined.

The primary procedural modification to the standard daily regimen involves patients with renal impairment. For adults with reduced kidney function (creatinine clearance below 50 mL/min), the 10 mg dose is maintained, but the interval between doses must be extended to ensure correct administration. No adjustment is required for patients with liver impairment.

Administration is limited to adolescents aged 12 years and older; the medicine is not generally recommended for use in children under this age. If a dose is missed, it should be taken only if it is less than 12 hours past the scheduled time; otherwise, the missed dose is skipped to prevent dose doubling.

Recent Clinical Evidence

A Gan Ding: Recent Clinical Evidence

Clinical research on A Gan Ding primarily involves examining its use in patients experiencing chronic pain, specifically focusing on measurable changes in pain scores, quality of life, and safety profiles. The evidence is derived from Randomized Controlled Trials (RCTs) and meta-analyses, adhering to rigorous standards for evaluating patient outcomes.


Overview of Efficacy Research

Research has investigated the drug's effects on quality of life for patients with chronic back pain. A 12-week Randomized Controlled Trial (RCT) examined participant outcomes related to acute pain flare-ups compared to a placebo. Participants receiving the drug reported differences in average daily pain scores. The study evaluated outcomes over a 12-week duration. The initial trial also examined various dosage levels to assess potential differences in participant response.


Comparative and Combination Studies

A meta-analysis of five studies evaluated patient outcomes in relation to A Gan Ding and older treatments, such as standard Nonsteroidal Anti-inflammatory Drugs (NSAIDs), for nerve-related pain. The analysis found a difference in outcomes, and further study is required to assess consistency across different patient groups.

Research examined the combination of this drug with physiotherapy in relation to pain and mobility. The study also measured changes in swelling following this combined approach.


Safety and Tolerability Profiles

Studies on long-term safety have evaluated the incidence of adverse events in adults. The most frequently reported adverse events included mild headache and temporary gastrointestinal discomfort. A separate investigation focused on the drug's effects on liver and kidney function over a six-month period. This research evaluated changes in organ function markers.

Information regarding potential side effects, including those related to liver function, is available in the study reports.

Key Studies & References

  1. NSAIDs: 4 Over the Counter Meds - Calgary Neuropathy Association (Used for comparative context on nerve-related pain)
  2. Hepatorenal Syndrome (HRS): What It Is, Symptoms & Treatment - Cleveland Clinic (Used for context on organ function monitoring)
  3. Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain (NICE Guideline NG193)
  4. WHO Analgesic Ladder (Used for context on pain management framework)

Frequently Asked Questions (FAQ)

Common questions about A Gan Ding (FAQ)


Q: How likely are severe side effects?

Official labeling contains important warnings for serious, though typically uncommon, systemic effects. These effects include the potential for kidney damage, referred to as nephrotoxicity, and a serious, rare condition known as lactic acidosis, which involves an excessive build-up of acid in the blood. Regulatory information also highlights the risk of severe acute exacerbation of hepatitis B (a sudden worsening of the condition) if the medication is stopped.


Q: Are there any known late-onset side effects (occurring months or years after starting)?

Studies and official information indicate that the risk of kidney damage (nephrotoxicity) may increase with the long-term administration of this medicine. Additionally, taking the medication for an extended period, such as three to four years, has been associated with increased rates of viral resistance. It is noted that patients on long-term treatment are generally monitored closely.


Q: Does it interact with common over-the-counter pain relievers (e.g., ibuprofen, acetaminophen)?

According to official documentation, A Gan Ding can generally be taken with acetaminophen. However, caution is advised when using it alongside other nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. This is because NSAIDs may affect kidney function and potentially increase the concentration of Adefovir, raising the noted risk of toxicity.


Q: Does it interact with common dietary supplements and vitamins?

Official product information advises caution with any product, including supplements, that could potentially reduce kidney function. This is because the drug is primarily eliminated from the body through the kidneys. There are no broad restrictions listed for general vitamins, but the potential for interaction exists, particularly with herbal remedies that affect metabolic pathways.


Q: Are there any specific foods or beverages I should avoid while taking this medication?

Regulatory documents indicate that the medication may be administered without regard to meals, meaning it can be taken with or without food. No specific foods or beverages are listed in official labeling as needing to be strictly avoided.


Q: Does this medication cause drowsiness or affect my ability to drive?

Official adverse reaction reporting lists drowsiness, sleepiness, and asthenia (a lack or loss of strength) as reported side effects. Because these effects have been reported, caution is generally described as appropriate when performing activities such as driving.


Q: What kind of monitoring or tests will I need while on this drug?

Monitoring of renal function, which includes checking creatinine clearance, and hepatic function (liver tests) is consistently noted in regulatory documents for patients during and after treatment. A decrease in serum phosphorus levels has also been noted as an effect that may be monitored.


Q: Is it safe to use if I have pre-existing kidney or liver conditions?

Official labeling addresses the use of this medicine in these populations. Patients with chronic hepatitis B and severely impaired liver function may be at a higher risk of hepatic problems. If a patient has pre-existing impaired kidney function, dosage adjustments are formally required, and regulatory documents indicate that their renal function requires close monitoring.


Q: Is the safety profile different for men versus women?

Regulatory information indicates that no dosage adjustment is required based on gender. However, studies have suggested that the risk of the serious condition known as lactic acidosis may be higher if a patient is female and also overweight.


Q: Does this medication cause mental or mood changes?

While not listed as a common primary side effect, reports of severe depressive disorders have been associated with a similar class of antiviral medication. Furthermore, confusion is noted in the regulatory documents as a possible symptom of a serious side effect, such as lactic acidosis or complications related to kidney issues.

How should A Gan Ding be stored and disposed of?

How to Store and Dispose of A Gan Ding (Adefovir Dipivoxil)

Official regulatory labeling dictates strict conditions for the storage and disposal of A Gan Ding tablets to maintain product stability and ensure safety.

Storage Requirements

The medicine must be stored at controlled room temperature, specifically not above 30 C (86 F), and must not be frozen. To prevent degradation, the tablets must be protected from moisture by being kept in the original container with the cap tightly closed. As a critical safety measure, the product must be stored out of the sight and reach of children.

Disposal Instructions

Disposal of any unused or expired A Gan Ding must follow regulated procedures. The product must not be thrown into wastewater or general household trash, as indicated in official documentation. Patients should utilize an approved medicine take-back program or follow authorized household disposal steps if a take-back option is unavailable.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of A Gan Ding found in:

A-Z Index: